Genetic polymorphisms of platelet receptors in patients with acute myocardial infarction and resistance to antiplatelet therapy

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 9, 2014, Pages 599-604

  Ulehlova, Jana ^a   Slavik, Ludek ^a   Kucerova, Jana ^a   Krcova, Vera ^a   Vaclavik, Jan ^b   Indrak, Karel ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; THROMBOCYTE ANTIGEN;

ADULT; AGED; DRUG RESISTANCE; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PILOT STUDY; POINT MUTATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, HUMAN PLATELET; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; POINT MUTATION; POLYMORPHISM, GENETIC;

EID: 84906893039     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2014.0077     Document Type: Article

References (16)

1. Abaci O, Kilickesmez KO (2013) Aspirin resistance: Where are we now? Anadolu Kardiol Derg 13:370-373.
2. Antoniades C, Tousoulis D, Vasiliadou C, et al. (2006) Genetic polymorphisms of platelet glycoprotein Ia and the risk for premature myocardial infarction: Effects on the release of sCD40L during the acute phase of premature myocardial infarction. J Am Coll Cardiol 47:1959-1966.
3. Blais N, Pharad C, Lordkipanidze M, et al. (2009) Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B2. Thromb Haemost 102:404-411.
4. Cattaneo M, Lecchi A, Zighetti ML, et al. (2007) Platelet aggregation studies: Autologous platelet poor plasma inhibits platelet aggregation when added to platelet rich plasma to normalize platelet count. Haematologica 92:694-697.
5. Cattaneo M (2007) Resistance to platelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 5:230-237.
6. Cuisset T, Frere C, Quilici J, et al. (2009) Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J 157:889-893.
7. Gurbel PA, Tandry US (2007) Clopidogrel resistance? Thromb Res 120:311-321.
8. Kvasnicka J, Hajkova J, Bobcikova P, et al. (2008) Polymorfizmy krevn?́ch desticek a moznosti monitorace úcinku protidestickové lécby. Interv Akut Kardiol 7:215-218.
9. Lepäntalo A, Mikkelsson J, Reséndiz JC, et al. (2006) Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 95:253-259.
10. Linnemann B, Schwonberg J, Mani H, et al. (2008) Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: An adjustment for platelet count is not necessary. J Thromb Haemost 6:677-683.
11. Mueller T, Dieplinger B, Poelz W, et al. (2007) Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer-comparison with two flow cytometric methods. Thromb Res 121:249-258.
12. Rudez G, Pons D, Leebeek F, et al. (2008) Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Hum Mutat 29:375-380.
13. Sevćková H (2006) Rezistence na protidesti-ckovou terapii. Interv Akut Kardiol 5:256-258.
14. Seyfert UT, Haubelt H, Vogt A, et al. (2007) Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 18:199-206.
15. Slavik L, U ́ lehlová J, Krcova V, et al. (2011) Detection of clopidogrel resistance by MEA and LTA. Transfuze a Hematologie Dnes 17:92-96.
16. Ú lehlová J, Slav́k L, Krcová V, et al. (2011) The assessment of aspirin resistance by using light transmission and multiple electrode aggregometry. Int J Lab Hematol 33:305-309.